Related Experiment Videos
Intravitreal bevacizumab for myopic choroidal neovascularization
Florian Rensch1, Ulrich H M Spandau, Frank Schlichtenbrede
1Department of Ophthalmology, Medical Faculty Mannheim of the Ruprecht-Karls-University Heidelberg, Mannheim, Germany.
Summary
Intravitreal bevacizumab injections significantly improved visual acuity and reduced retinal thickness in patients with myopic choroidal neovascularization. This treatment shows promise for exudative myopic macular degeneration.
Area of Science:
- Ophthalmology
- Retinal Diseases
- Vascular Biology
Background:
- Myopic choroidal neovascularization (mCNV) is a leading cause of vision loss in high myopia.
- Exudative mCNV can lead to rapid and irreversible visual impairment.
Purpose of the Study:
- To assess the efficacy of intravitreal bevacizumab in improving visual acuity for patients with mCNV.
- To evaluate changes in retinal thickness and intraocular pressure following treatment.
Main Methods:
- Retrospective case series of 13 patients with mCNV.
- Three intravitreal injections of 1.5 mg bevacizumab administered per patient.
- Visual acuity and central retinal thickness measured via optical coherence tomography.
Main Results:
- Significant improvement in mean visual acuity from baseline (0.63 LogMAR) at 1, 3, and 6 months post-injection (0.39, 0.47, 0.52 LogMAR, respectively).
- Significant decrease in central retinal thickness correlated with visual acuity gains.
- No significant change in intraocular pressure observed during the follow-up period.
Conclusions:
- Intravitreal bevacizumab is a potential therapeutic option for exudative myopic macular degeneration.
- The treatment effectively improves vision and reduces retinal thickening in mCNV patients.
Related Concept Videos
01:27Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:28Angle Closure Glaucoma: Treatment
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
01:27Diabetic Retinopathy
DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...
01:25Glaucoma: Overview
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...